Patrice Viens

List of Publications by Year
in descending order

179 papers	15,188 citations	34016 52 h-index	17546 121 g-index
193 all docs	193 docs citations	193 times ranked	19584 citing authors

#	Article	IF	Citations
1	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. Npj Breast Cancer, 2022, 8, 12.	2.3	6
2	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Medicine, 2021, 13, 87.	3.6	24
3	A study of elite sport-inspired coaching for patients after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2755-2762.	1.3	2
4	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. OncoImmunology, 2021, 10, 1929724.	2.1	22
5	Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study. Bone Marrow Transplantation, 2021, , .	1.3	0
6	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in nonâ€inflammatory breast cancers. Molecular Oncology, 2020, 14, 504-519.	2.1	23
7	REBOUND â€œTrained to live againâ€ The practice of great Olympic coaches improves and enhances the quality of life of cancer patients in remission after hematopoietic stem cell allogeneic transplantation. Bone Marrow Transplantation, 2020, 55, 997-999.	1.3	5
8	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. Cancers, 2019, 11, 1158.	1.7	6
9	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. Cancers, 2019, 11, 1033.	1.7	160
10	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Medicine, 2019, 8, 612.	1.0	5
11	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. Cancers, 2019, 11, 665.	1.7	25
12	High Response to Cetuximab in a Patient With <i>EGFR</i>-Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2019, 3, 1-8.	1.5	5
13	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 560-567.	3.0	206
14	Safety and efficacy of eribulin for â€œreal-worldâ€ older patients with metastatic breast cancer. Journal of Geriatric Oncology, 2018, 9, 281-283.	0.5	14
15	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. Oncotarget, 2018, 9, 33762-33777.	0.8	17
16	Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. Cancer Research and Treatment, 2018, 50, 1226-1237.	1.3	10
17	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. British Journal of Cancer, 2018, 119, 1383-1391.	2.9	54
18	Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France. Medical Decision Making, 2017, 37, 555-566.	1.2	5

#	Article	IF	Citations
19	The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. Expert Review of Anticancer Therapy, 2017, 17, 593-606.	1.1	3
20	Optimal duration of adjuvant chemotherapy for high-risk node-negative (N€") breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). European Journal of Cancer, 2017, 79, 166-175.	1.3	5
21	A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study. Supportive Care in Cancer, 2017, 25, 2715-2722.	1.0	4
22	Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Annals of Oncology, 2017, 28, 769-776.	0.6	77
23	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. European Journal of Cancer, 2017, 86, 28-36.	1.3	48
24	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Annals of Oncology, 2017, 28, 103-109.	0.6	52
25	Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy. Cancer Research, 2017, 77, S3-01-S3-01.	0.4	7
26	MARCKS protein overexpression in inflammatory breast cancer. Oncotarget, 2017, 8, 6246-6257.	0.8	27
27	Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory *versus* locally advanced breast cancers. Oncotarget, 2017, 8, 66019-66032.	0.8	10
28	Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. Journal of Cancer, 2016, 7, 2077-2084.	1.2	6
29	High-dose chemotherapy for inflammatory breast cancer: impact of immunohistochemical status on survival outcome. Annals of Oncology, 2016, 27, vi93.	0.6	0
30	Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 1082-1086.	1.3	13
31	Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. Breast, 2016, 27, 8-14.	0.9	5
32	SPAG5: the ultimate marker of proliferation in early breast cancer?. Lancet Oncology, The, 2016, 17, 863-865.	5.1	11
33	Contribution of FDG PET/CT for the Optimization of the Management of Additional Lesions Detected on Local Staging Breast MRI. American Journal of Roentgenology, 2016, 206, 891-900.	1.0	6
34	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2016, 17, 600-611.	5.1	43
35	Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. Familial Cancer, 2016, 15, 497-506.	0.9	10
36	A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study. Chemotherapy, 2016, 61, 15-22.	0.8	2

#	Article	IF	Citations
37	Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. European Journal of Cancer, 2016, 57, 118-126.	1.3	5
38	Bevacizumab in HER2-negative inflammatory breast cancer. Oncoscience, 2016, 3, 297-298.	0.9	2
39	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, 2016, 7, 79428-79441.	0.8	11
40	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7, 18531-18540.	0.8	38
41	Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget, 2016, 7, 27208-27219.	0.8	69
42	Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasisâ€"a case control study. Oncotarget, 2016, 7, 45649-45655.	0.8	26
43	Abstract P4-13-23: Next-generation sequencing (NGS), array comparative genomic hybridization (aCGH) and patient-derived tumor xenograft (PDX) for precision medicine in advanced breast cancer: A single-center prospective study. , 2016, , .		0
44	METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors. Anticancer Research, 2016, 36, 293-9.	0.5	7
45	2359 Optimal therapeutic sequences in the treatment of metastatic pancreatic cancer - a retrospective analysis from two Canadian and French tertiary cancer centres. European Journal of Cancer, 2015, 51, S455.	1.3	0
46	2354 Is pancreatic adenocarcinoma more aggressive in adolescents and young adults? A multi-institute retrospective study. European Journal of Cancer, 2015, 51, S453.	1.3	0
47	Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. BMC Cancer, 2015, 15, 697.	1.1	3
48	Prognostic Factors for Ovarian Epithelial Cancer in the Elderly. International Journal of Gynecological Cancer, 2015, 25, 815-822.	1.2	29
49	Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, 2015, 6, 5449-5464.	0.8	424
50	Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer. PLoS ONE, 2015, 10, e0123768.	1.1	43
51	<i>PDL1</i> expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, 2015, 6, 13506-13519.	0.8	105
52	P-037 Advanced Pancreatic Cancer Patients' Characteristics, Treatment and Outcome Based on Three Age Groups: â‰¤39, 39-74 and â‰¥ 75, a Report from Single Cancer Institution. Annals of Oncology, 2015, 26, iv10.	0.6	0
53	Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data. Clinical Cancer Research, 2015, 21, 1298-1304.	3.2	56
54	Transcriptomic Analysis Predicts Survival and Sensitivity to Anticancer Drugs of Patients with a Pancreatic Adenocarcinoma. American Journal of Pathology, 2015, 185, 1022-1032.	1.9	46

#	Article	IF	Citations
55	UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxelâ€"5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Annals of Oncology, 2015, 26, 1692-1697.	0.6	16
56	Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.. Journal of Clinical Oncology, 2015, 33, 108-108.	0.8	2
57	A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Oncotarget, 2015, 6, 746-754.	0.8	21
58	Effect of high MMP2 and low MMP9 baseline serum levels on outcome in patients with HER2-positive inflammatory breast cancer (IBC) treated with bevacizumab (BEV)- and trastuzumab (TRA)-based neoadjuvant chemotherapy (NAC) in the BEVERLY 2 study.. Journal of Clinical Oncology, 2015, 33, 600-600.	0.8	0
59	Pancreatic neuroendocrine tumors (pNET) in adolescent and young adult (AYA) population: A multi-institutional study of characteristics and outcomes.. Journal of Clinical Oncology, 2015, 33, e15173-e15173.	0.8	0
60	Pancreatic adenocarcinoma in adolescent and young adults (18-44): Characteristics and clinical outcomes from Canada and France.. Journal of Clinical Oncology, 2015, 33, e15215-e15215.	0.8	0
61	Abstract 381: Circulating tumor cells (CTC) but not circulating endothelial cells (CEC) are independent prognostic factors in neoadjuvant chemotherapy combined with bevacizumab in HER2 negative inflammatory breast cancer (IBC) in multicentre phase II trial BEVERLY1. , 2015, , .		0
62	Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling. PLoS ONE, 2014, 9, e81843.	1.1	53
63	Carcinomatous Myelitis and Meningitis after a Squamous Cell Carcinoma of the Lip. Case Reports in Oncology, 2014, 7, 33-38.	0.3	3
64	Circulating Tumor Cell Count at Baseline is an Independent Prognostic Factor from Pathological Complete Response Among Patients Treated for Primary Inflammatory Her2-Positive Breast Cancer: Survival Results of the Beverly-2 Study. Annals of Oncology, 2014, 25, iv110.	0.6	1
65	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Molecular Cancer, 2014, 13, 228.	7.9	91
66	Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of Oncology, 2014, 25, 358-365.	0.6	82
67	Assessment of prognostic scores in brain metastases from breast cancer. Neuro-Oncology, 2014, 16, 421-428.	0.6	21
68	Clinical development of mTOR inhibitors in breast cancer. Breast Cancer Research, 2014, 16, 203.	2.2	49
69	EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Cancer Letters, 2014, 355, 70-75.	3.2	44
70	Genomic profiling of inflammatory breast cancer: A review. Breast, 2014, 23, 538-545.	0.9	46
71	Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review. Supportive Care in Cancer, 2013, 21, 2359-2369.	1.0	3
72	ALDH1-Positive Cancer Stem Cells Predict Engraftment of Primary Breast Tumors and Are Governed by a Common Stem Cell Program. Cancer Research, 2013, 73, 7290-7300.	0.4	103

#	Article	IF	Citations
73	BetaHCG secretion by a pulmonary adenocarcinoma. World Journal of Surgical Oncology, 2013, 11, 228.	0.8	10
74	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. Clinical Cancer Research, 2013, 19, 4685-4696.	3.2	130
75	Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Research and Treatment, 2013, 138, 761-772.	1.1	56
76	Prediction of BRCA1 Germ-Line Mutation Status in Patients with Breast Cancer Using Histoprognosis Grade, MS110, Lys27H3, Vimentin, and KI67. Pathobiology, 2013, 80, 219-227.	1.9	12
77	Breast Cancer Patients' Views on the Use of Genomic Testing to Guide Decisions about Their Postoperative Chemotherapy. Public Health Genomics, 2013, 16, 110-117.	0.6	9
78	Difference in Therapeutic Response Between Basal and Nonbasal Triple–Negative Breast Cancers. Oncologist, 2013, 18, 1060-1061.	1.9	3
79	Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Annals of Oncology, 2013, 24, 1231-1238.	0.6	59
80	Young breast cancer patients' involvement in treatment decisions: the major role played by decision–making about surgery. Psycho-Oncology, 2013, 22, 2546-2556.	1.0	20
81	Complementary or Alternative Medicine as Possible Determinant of Decreased Persistence to Aromatase Inhibitor Therapy among Older Women with Non-Metastatic Breast Cancer. PLoS ONE, 2013, 8, e81677.	1.1	23
82	Abstract P6-12-08: Serum biomarkers identification using quantitative proteomics in patients with HER2-positive inflammatory breast cancer receiving trastuzumab plus bevacizumab-based chemotherapy (BEVERLY 2 trial). , 2013, , .		0
83	Abstract P6-12-06: Three-year follow up results of a phase II study of neoadjuvant bevacizumab, chemotherapy, and trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY2 study. , 2013, , .		0
84	Abstract P2-05-04: Comparative expression profiling of patient samples and preclinical models of inflammatory breast cancer reveals gene signatures of epithelial plasticity and suppression of TGFb signaling. , 2013, , .		0
85	Transparency in the presentation of trial results may not increase patients' trust in medical researchers. Clinical Trials, 2012, 9, 90-93.	0.7	2
86	Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplantation, 2012, 47, 549-555.	1.3	42
87	BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals of Oncology, 2012, 23, 2799-2805.	0.6	184
88	Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups. Clinical Cancer Research, 2012, 18, 1555-1560.	3.2	27
89	Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?. Annals of Oncology, 2012, 23, 714-721.	0.6	56
90	Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncology, The, 2012, 13, 420-432.	5.1	61

#	Article	IF	Citations
91	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncology, The, 2012, 13, 375-384.	5.1	160
92	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. European Respiratory Journal, 2012, 39, 172-179.	3.1	43
93	Self-Reported Cognitive Impairment After Breast Cancer Treatment in Young Women from the ELIPPSE40 Cohort: The Long-Term Impact of Chemotherapy. Breast Journal, 2012, 18, 406-414.	0.4	18
94	Patientsâ€™ regrets after participating in a randomized controlled trial depended on their involvement in the decision making. Journal of Clinical Epidemiology, 2012, 65, 635-642.	2.4	23
95	Early discontinuation of tamoxifen intake in younger women with breast cancer: Is it time to rethink the way it is prescribed?. European Journal of Cancer, 2012, 48, 1939-1946.	1.3	87
96	Association of carcinoid tumor and low grade glioma. World Journal of Surgical Oncology, 2012, 10, 236.	0.8	2
97	Microarray Analysis Identifies an Expression Signature for Inflammatory Breast Cancer. , 2012, , 243-258.		0
98	Are there candidates for high-dose chemotherapy in ovarian carcinoma?. Journal of Experimental and Clinical Cancer Research, 2012, 31, 87.	3.5	7
99	8q24 Cancer Risk Allele Associated with Major Metastatic Risk in Inflammatory Breast Cancer. PLoS ONE, 2012, 7, e37943.	1.1	34
100	Tumor Selective Cytotoxic Action of a Thiomorpholin Hydroxamate Inhibitor (TMI-1) in Breast Cancer. PLoS ONE, 2012, 7, e43409.	1.1	4
101	Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target. Stem Cells, 2012, 30, 1327-1337.	1.4	120
102	Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. Breast Cancer Research and Treatment, 2012, 132, 1035-1047.	1.1	14
103	Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretations and positive attitudes. European Journal of Cancer Care, 2012, 21, 242-250.	0.7	29
104	Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study. , 2012, , 225-242.		0
105	Abstract 5339: Breast cancer stem cells predict engraftmentin vivoof primary tumor and are characterized by a gene expression signature associated with poor prognosis.. , 2012, , .		0
106	Abstract 2368: Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non metastatic breast cancer. , 2012, , .		0
107	Abstract P3-12-11: Clinical outcome in patients with surgically resected brain metastases from breast cancer: prognostic considerations regarding molecular status and established prognostic classification systems.. , 2012, , .		0
108	Abstract P1-13-04: Optimal duration of adjuvant chemotherapy for high risk node negative breast cancer patients: 6-year results of the prospective randomized phase III trial PACS 05.. , 2012, , .		1

#	Article	IF	Citations
109	Recent trends in epidemiology of brain metastases: an overview. Anticancer Research, 2012, 32, 4655-62.	0.5	233
110	A seven-gene prognostic model for platinum-treated ovarian carcinomas. British Journal of Cancer, 2011, 105, 304-311.	2.9	37
111	International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology, 2011, 22, 515-523.	0.6	407
112	Peritumoural vascular invasion: A major determinant of triple-negative breast cancer outcome. European Journal of Cancer, 2011, 47, 1537-1545.	1.3	26
113	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial. Breast Cancer Research, 2011, 13, R109.	2.2	24
114	A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Research and Treatment, 2011, 126, 407-420.	1.1	231
115	Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment, 2011, 127, 363-373.	1.1	11
116	Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2011, 127, 273-281.	1.1	66
117	Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. Breast Cancer Research and Treatment, 2011, 129, 401-409.	1.1	5
118	L'après cancer : mise en place du plan personnalisé de l'après cancer (PPAC). Oncologie, 2011, 13, 271-276.	0.2	0
119	Kinome expression profiling and prognosis of basal breast cancers. Molecular Cancer, 2011, 10, 86.	7.9	46
120	Full access to medical records does not modify anxiety in cancer patients. Cancer, 2011, 117, 4796-4804.	2.0	28
121	Predictive Factors of Tumor Response After Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 483-491.	0.4	68
122	PD03-01: An Integrated Analysis of Three Distinct IBC/nIBC Affymetrix Gene Expression Data Sets Further Unveils the Molecular Biology of IBC.. , 2011, , .		4
123	Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. Journal of Clinical Investigation, 2011, 121, 3609-3622.	3.9	524
124	BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.. Journal of Clinical Oncology, 2011, 29, 4028-4028.	0.8	9
125	High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes. PLoS ONE, 2011, 6, e16950.	1.1	57
126	Abstract 328: An integrated analysis of three distinct IBC/non-IBC Affymetrix gene expression data sets to study the transcriptional heterogeneity both between IBC and non-IBC and within IBC. , 2011, , .		0

#	Article	IF	Citations
127	Accuracy of endorectal ultrasonography in evaluation of response to chemoradiation in locally advanced rectal cancer.. Journal of Clinical Oncology, 2011, 29, 3543-3543.	0.8	0
128	Postoperative complications in neoadjuvant treatment including bevacizumab for HER2-positive inflammatory breast cancer (IBC): Results from a phase II prospective trial.. Journal of Clinical Oncology, 2011, 29, 569-569.	0.8	0
129	Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT), and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEVERLY2 study.. Journal of Clinical Oncology, 2011, 29, 531-531.	0.8	1
130	P5-01-01: Identification, Validation and Assessment of Transcriptional Relevance of a PDGFR-Activation Signature in (Inflammatory) Breast Cancer.. , 2011, , .		0
131	P4-20-01: Multicentric Phase II PACS 09/Beverly1 Trial: First Efficacy and Safety Results of Neoadjuvant Chemotherapy Combined with Bevacizumab in HER2ˆˉNegative Patients with Non-Metastatic Inflammatory Breast Cancer.. , 2011, , .		1
132	P1-14-02: Correlation of Circulating Tumor Cells (CTC) and Circulating Endothelial Cells (CEC) with Pathological Complete Response (pCR) during Neoadjuvant Chemotherapy (CT) Combined with Bevacizumab in HER2 Negative Inflammatory Breast Cancer (IBC): Ancillary Study of Phase II Trial BEVERLY 1.. , 2011, , .		0
133	Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Research, 2011, 31, 1079-86.	0.5	14
134	Genome profiling of ERBB2-amplified breast cancers. BMC Cancer, 2010, 10, 539.	1.1	136
135	Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature. BMC Cancer, 2010, 10, 645.	1.1	28
136	Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 2010, 38, 55-60.	0.2	16
137	Gene expression profiling of inflammatory breast cancer. Cancer, 2010, 116, 2783-2793.	2.0	45
138	Systemic therapy of inflammatory breast cancer from highâ€dose chemotherapy to targeted therapies. Cancer, 2010, 116, 2829-2836.	2.0	15
139	Allogeneic hematopoietic stem cell transplantation in ovarian cancerâ€"the EBMT experience. International Journal of Cancer, 2010, 127, 1446-1452.	2.3	9
140	Prescribersâ€™ attitudes toward elderly breast cancer patients. Discrimination or empathy?. Critical Reviews in Oncology/Hematology, 2010, 75, 138-150.	2.0	50
141	Resection of residual masses after chemotherapy for advanced non-seminomatous germ cell tumours, a monocentric analysis of pre-operative prognosticators. European Journal of Cancer Care, 2010, 19, 827-832.	0.7	3
142	Participantsâ€™ uptake of clinical trial results: a randomised experiment. British Journal of Cancer, 2010, 102, 1081-1084.	2.9	18
143	Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. Annals of Oncology, 2010, 21, 1448-1454.	0.6	15
144	Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer. Current Medical Research and Opinion, 2010, 26, 1065-1073.	0.9	10

#	Article	IF	Citations
145	Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer. Clinical Cancer Research, 2010, 16, 45-55.	3.2	646
146	Loss, mutation and deregulation of L3MBTL4 in breast cancers. Molecular Cancer, 2010, 9, 213.	7.9	63
147	Abstract P2-16-05: BEVERLY2, a Phase II Study Evaluating Bevacizumab (BEV) Combined with Chemotherapy (CT) and Trastuzumab (H) as Neoadjuvant Therapy for HER2-Positive Inflammatory Breast Cancer (IBC): First Efficacy Results. , 2010, , .		1
148	Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: Response, survival, and prognostic factors.. Journal of Clinical Oncology, 2010, 28, 2593-2593.	0.8	0
149	Abstract PD04-07: Monitoring Circulating Tumor Cells (CTC) and Circulating Endothelial Cells (CEC) during Neoadjuvant Combination of Trastuzumab and Bevacizumab with Chemotherapy in HER2 Overexpressing Inflammatory Breast Cancer (IBC): An Ancillary Study of BEVERLY 2 Multicenter Phase II Trial. , 2010, , .		0
150	How different are luminal A and basal breast cancers?. International Journal of Cancer, 2009, 124, 1338-1348.	2.3	51
151	Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature. Cancer Research, 2009, 69, 1302-1313.	0.4	1,067
152	Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. Anti-Cancer Drugs, 2009, 20, 946-952.	0.7	6
153	How basal are triple–negative breast cancers?. International Journal of Cancer, 2008, 123, 236-240.	2.3	384
154	Defining the Molecular Biology of Inflammatory Breast Cancer. Seminars in Oncology, 2008, 35, 41-50.	0.8	52
155	Sixteen–Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis. Cancer Research, 2008, 68, 767-776.	0.4	105
156	Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes. Molecular and Cellular Proteomics, 2008, 7, 1420-1433.	2.5	74
157	Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica, 2007, 92, 1004-1006.	1.7	74
158	Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology, 2007, 25, 3407-3414.	0.8	367
159	Integrated Profiling of Basal and Luminal Breast Cancers. Cancer Research, 2007, 67, 11565-11575.	0.4	254
160	ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell, 2007, 1, 555-567.	5.2	3,550
161	Gene Expression Profiling and Clinical Outcome in Breast Cancer. OMICS A Journal of Integrative Biology, 2006, 10, 429-443.	1.0	60
162	Gene Expression Profiling Shows Medullary Breast Cancer Is a Subgroup of Basal Breast Cancers. Cancer Research, 2006, 66, 4636-4644.	0.4	273

#	ARTICLE	IF	CITATIONS
163	Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer, 2006, 6, 245.	1.1	120
164	Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. Journal of Clinical Oncology, 2006, 24, 5664-5671.	0.8	512
165	Gene Expression Profiling Identifies Molecular Subtypes of Inflammatory Breast Cancer. Cancer Research, 2005, 65, 2170-2178.	0.4	229
166	Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Research, 2005, 65, 767-79.	0.4	148
167	Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy. Cancer Research, 2004, 64, 8558-8565.	0.4	177
168	Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene, 2004, 23, 1377-1391.	2.6	293
169	Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene, 2004, 23, 2564-2575.	2.6	117
170	Immunophenotypic analysis of inflammatory breast cancers: identification of an'inflammatory signature'. Journal of Pathology, 2004, 202, 265-273.	2.1	180
171	Comparative multi-methodological measurement of ERBB2 status in breast cancer. Journal of Pathology, 2004, 202, 286-298.	2.1	61
172	Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood, 2004, 103, 435-441.	0.6	125
173	Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. International Journal of Cancer, 2003, 107, 854-862.	2.3	19
174	Can Sequential Administration Minimise the Cost of High Dose Chemotherapy?. Pharmacoeconomics, 2003, 21, 807-818.	1.7	1
175	High-Dose Chemotherapy for Breast Cancer: The French PEGASE Experience. Cancer Control, 2003, 10, 42-47.	0.7	79
176	Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Human Molecular Genetics, 2002, 11, 863-872.	1.4	117
177	Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers. American Journal of Pathology, 2002, 161, 1223-1233.	1.9	144
178	High-Dose Sequential Chemotherapy With Recombinant Granulocyte Colony-Stimulating Factor and Repeated Stem-Cell Support for Inflammatory Breast Cancer Patients: Does Impact on Quality of Life Jeopardize Feasibility and Acceptability of Treatment?. Journal of Clinical Oncology, 2000, 18, 754-754.	0.8	62
179	Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma. Cancer, 1999, 85, 2190-2199.	2.0	37